
SeaBeLife secures €1.2m in funding
SeaBeLife SAS has secured €1.2m in funding, aiming to develop unique drug candidates that block cell necrosis and target two regulated cell death...

Sanofi licences vaccine against bacterial sepsis
Extraintestinal pathogenic E. coli (ExPEC) is a leading bacterial cause of sepsis, causing approximately 10 million cases of invasive E. coli...

Breakthrough in microtia treatment
Researchers of the Tissue Engineering and Biofabrication Laboratory of the ETH Zurich unveiled a novel approach to addressing microtia, a congenital...

AMR: Partnership set to improve in vivo antibiotics testing
The development of novel antibiotics is crucial in the fight against antimicrobial resistance (AMR) but has been neglected for decades due to a lack...

Pierre Fabre SA licences immunotherapy from Atara Biotherapeutics
Paris-based Pierre Fabre Laboratories SA already held a licence for the EU-approved tabelecleucel, an allogeneic T cell based second-line treatment...

AstronauTx closes £48m Series A financing
The finanicing round of AstronauTx Ltd was led by the Novartis Venture Fund, with participation of MPM Capital, Brandon Capital, EQT Life Sciences,...

Quotient Therapeutics kicks-off with US$50m financing
Flagship has confírmed to invest $50m in Quotient Therapeutics to advance development of a platform, licenced from Wellcome Sanger Institue...